NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell DeathData Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- ...

NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738 BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) ...

BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) ("NuCana” or the "Company”) presented data at the European Society for Medical Oncology Congress 2025 ("ESMO”) on a new model system ...

Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancers First-in-class multi-checkpoint inhibitor with robust ...

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's ...

NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off Shows ...

NuCana (NCNA) presented data at the European Society for Medical Oncology Congress 2025, ESMO, on a new model system investigating the synergistic ...

Camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031.

Celltrion announced on the 31st that it has signed a joint research and development agreement for a new immuno-oncology drug with MustBio, a domestic ...

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's ...

"ESMO 2025: Padcev plus Keytruda promising in first-line advanced HNSCC" was originally created and published by Clinical ...